189 related articles for article (PubMed ID: 21381292)
1. [Treatment of chronic graft-versus-host disease with protein tyrosine kinase inhibitors].
Martínez C
Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():69-71. PubMed ID: 21381292
[TBL] [Abstract][Full Text] [Related]
2. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
Moreno-Romero JA; Fernández-Avilés F; Carreras E; Rovira M; Martínez C; Mascaró JM
Arch Dermatol; 2008 Sep; 144(9):1106-9. PubMed ID: 18794453
[No Abstract] [Full Text] [Related]
3. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease.
Jurado M; Vallejo C; Pérez-Simón JA; Brunet S; Ferra C; Balsalobre P; Pérez-Oteyza J; Espigado I; Romero A; Caballero D; Sierra J; Ribera JM; Díez JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):701-6. PubMed ID: 17531780
[TBL] [Abstract][Full Text] [Related]
4. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
Wolff D; Gerbitz A; Ayuk F; Kiani A; Hildebrandt GC; Vogelsang GB; Elad S; Lawitschka A; Socie G; Pavletic SZ; Holler E; Greinix H
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1611-28. PubMed ID: 20601036
[TBL] [Abstract][Full Text] [Related]
5. The management and outcome of chronic graft-versus-host disease.
Fraser CJ; Scott Baker K
Br J Haematol; 2007 Jul; 138(2):131-45. PubMed ID: 17593020
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.
Uberti JP; Ayash L; Braun T; Reynolds C; Silver S; Ratanatharathorn V
Bone Marrow Transplant; 2004 Sep; 34(5):425-31. PubMed ID: 15273705
[TBL] [Abstract][Full Text] [Related]
7. Chronic graft versus host disease of oral mucosa: review of available therapies.
Imanguli MM; Pavletic SZ; Guadagnini JP; Brahim JS; Atkinson JC
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Feb; 101(2):175-83. PubMed ID: 16448918
[TBL] [Abstract][Full Text] [Related]
8. Oral graft-versus-host disease.
Schubert MM; Correa ME
Dent Clin North Am; 2008 Jan; 52(1):79-109, viii-ix. PubMed ID: 18154866
[TBL] [Abstract][Full Text] [Related]
9. A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy.
Lazar J; Poonawalla T; Teng JM
Pediatr Dermatol; 2011; 28(2):172-5. PubMed ID: 21504445
[TBL] [Abstract][Full Text] [Related]
10. Replacement of calcineurin inhibitors with daclizumab in patients with transplantation-associated microangiopathy or renal insufficiency associated with graft-versus-host disease.
Wolff D; Wilhelm S; Hahn J; Gentilini C; Hilgendorf I; Steiner B; Kahl C; Junghanss C; Hartung G; Casper J; Uharek L; Holler E; Freund M
Bone Marrow Transplant; 2006 Sep; 38(6):445-51. PubMed ID: 16951692
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
Kharfan-Dabaja MA; Bazarbachi A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
13. Ocular graft-versus-host disease: a review.
Shikari H; Antin JH; Dana R
Surv Ophthalmol; 2013; 58(3):233-51. PubMed ID: 23541042
[TBL] [Abstract][Full Text] [Related]
14. Many faces of graft-versus-host disease.
Peñas PF; Zaman S
Australas J Dermatol; 2010 Feb; 51(1):1-10; quiz 11. PubMed ID: 20148830
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S
Bone Marrow Transplant; 2003 Jul; 32(2):165-70. PubMed ID: 12838281
[TBL] [Abstract][Full Text] [Related]
16. B-cell involvement in chronic graft-versus-host disease.
Kapur R; Ebeling S; Hagenbeek A
Haematologica; 2008 Nov; 93(11):1702-11. PubMed ID: 18728020
[TBL] [Abstract][Full Text] [Related]
17. Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome.
Skert C; Patriarca F; Sperotto A; Cerno M; Filì C; Zaja F; Stocchi R; Geromin A; Damiani D; Fanin R
Haematologica; 2006 Feb; 91(2):258-61. PubMed ID: 16461315
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
Distler JH; Distler O
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
[TBL] [Abstract][Full Text] [Related]
19. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
Maziarz RT
Curr Opin Hematol; 2008 Mar; 15(2):127-33. PubMed ID: 18300759
[TBL] [Abstract][Full Text] [Related]
20. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
